Dr. David Crean Book Guides Biopharma Leaders on Commercialization
Dr. David H. Crean has released Dual Fluency: Bridging Science, Capital, and Governance in Life Sciences, a guide for biopharma leaders navigating the gap between early discovery and commercialization. The book addresses why many approved therapeutics fail to recover development costs and outlines methods for translating scientific data into investable valuations, structuring partnerships and licensing deals, and improving board-level asset management. It also discusses capital-stack strategies, including BARDA grants, royalty monetization, venture debt, and crossover investment, intended to reduce unnecessary equity dilution. The book is aimed at scientist-founders, pre-commercial executives, business development professionals, and healthcare investors, and is expected to become available through Amazon and major bookstores.
Where do you stand?
How it spread



